Physician profile
Christopher Barber
NPI 1164467379
$10,594.18
in general payments reported to CMS, 2019-2025
47 companies · $1,359 in 2025
The $1,359 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,526 · 2020: $370 · 2021: $1,874 · 2022: $2,370 · 2023: $1,862 · 2024: $1,233 · 2025: $1,359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,454.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,453.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,365.00 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Astrazeneca Pharmaceuticals Lp | $1,208.38 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,173.74 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $975.14 | 2019-2025 | |
| Abbvie INC. | $940.96 | 2019-2025 | Vraylar, Qulipta, Viberzi |
| Glaxosmithkline, LLC. | $734.60 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $592.64 | 2019-2025 | Jardiance, Ofev |
| Amgen INC. | $461.61 | 2019-2025 | Otezla, Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $387.82 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $348.27 | 2019-2025 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $290.98 | 2019-2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $251.03 | 2019-2024 | |
| Kowa Pharmaceuticals America, INC. | $215.96 | 2019-2023 | Livalo, Seglentis |
| Janssen Pharmaceuticals, INC | $193.76 | 2019-2022 | |
| Amarin Pharma, INC. | $100.14 | 2019-2022 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Barber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.